Novartis (NVS) announced that it has increased its sales guidance for the mid-term. The company now expects total sales to witness a compound annual growth rate (CAGR) of 6% during 2023-2028 compared with the previous estimate of 5%.The rise in guidance was due to the strong momentum of NVS’ key drugs and its upcoming launches.Shares of Novartis have risen 4% year to date compared with the industry’s growth of 4.8%.Image Source: Zacks Investment ResearchNVS Raises Mid-Term OutlookFor 2024-2029, sales are ex ...